First Trust Advisors LP Has $7.09 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

First Trust Advisors LP raised its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 43.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 176,220 shares of the company's stock after purchasing an additional 53,175 shares during the quarter. First Trust Advisors LP owned 0.27% of Kymera Therapeutics worth $7,089,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Blue Trust Inc. increased its stake in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after buying an additional 270 shares during the last quarter. KBC Group NV increased its position in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after acquiring an additional 752 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after acquiring an additional 406 shares in the last quarter. PEAK6 LLC bought a new stake in Kymera Therapeutics during the fourth quarter worth about $302,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Kymera Therapeutics during the fourth quarter valued at approximately $310,000.

Kymera Therapeutics Trading Up 2.1 %

Shares of NASDAQ:KYMR traded up $0.73 during trading on Friday, reaching $35.28. 640,377 shares of the stock were exchanged, compared to its average volume of 556,422. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27. The stock has a 50-day moving average price of $29.68 and a 200-day moving average price of $38.26. The firm has a market cap of $2.29 billion, a PE ratio of -15.08 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 2,241 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the transaction, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at $2,064,510. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,659 shares of company stock worth $324,567. Corporate insiders own 15.82% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on KYMR shares. Citigroup started coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. Stephens reiterated an "overweight" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, HC Wainwright lifted their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.